Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel. | March 24, 2023
Regulatory approval for proof of pharmacology study for the first non-antibiotic macrolide EpiEndo Pharmaceuticals ('EpiEndo'), the clinical-stage biopharmaceutical company developing disease-modifying
Regulatory approval for proof of pharmacology study for the first non-antibiotic macrolideREYKJAVIK, Iceland, August 31, 2022 / B3C newswire / EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has received.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.